What are the infusion reactions to remicade?

What happens during a typical infusion reaction to Remicade?

Infusion reactions to infliximab occur in roughly 20% of patients. Symptoms usually emerge during or within two hours of the treatment session. Common complaints include fever, chills, chest pain, low blood pressure, and itching or hives. More severe cases show breathing difficulty, high blood pressure, and anaphylaxis. Mild reactions often improve with slower infusion rates or antihistamines and steroids given before treatment.

How do doctors manage an ongoing reaction?

Stop the infusion immediately if any serious symptom develops. Restart at a slower rate once symptoms settle. Premedication with acetaminophen, diphenhydramine, and sometimes corticosteroids is widely adopted for patients who have previously experienced reactions. Some centers use slower overall infusion speeds across all sessions to avoid problems.

What happens when a patient develops antibodies against Remicade?

Antibodies to infliximab are common and correlate with both acute infusion reactions and delayed serum sickness reactions. Delayed reactions appear three to twelve days later and include fever, rash, arthralgias, and myalgias. Patients with detectable antibodies often see lower drug levels and higher risk of treatment failure. Premedication and slower rates do not always ausreichend protect them.

What alternatives exist for patients intolerant to Remicade?

Patients who cannot tolerate infliximab infusions regularly switch to other TNF inhibitors such as adalimumab, etanercept, or golimumab. These agents are mostly subcutaneous rather than intravenous. Biosimilars of infliximab also exist, but they produce similar reaktions rates.